The full content of Annals is available to subscribers

Subscribe/Learn More  >
Letters |

Successful Treatment of Diffuse Pulmonary Lymphangiomatosis With Bevacizumab

Jurjan Aman, MD; Erik Thunnissen, MD, PhD; Marinus A. Paul, MD, PhD; Geerten P. van Nieuw Amerongen, PhD; and Anton Vonk-Noordegraaf, MD, PhD
[+] Article, Author, and Disclosure Information

From VU University Medical Center, Amsterdam, the Netherlands.

Acknowledgment: The authors thank Dr. Jackeline Agorreta, University of Navarra, Pamplona, Spain, for her contribution.

Potential Conflicts of Interest: None disclosed.

Ann Intern Med. 2012;156(11):839-840. doi:10.7326/0003-4819-156-11-201206050-00016
Text Size: A A A


Grahic Jump Location

Treatment and characterization of diffuse pulmonary lymphangiomatosis.

A. Treatment effects of bevacizumab on blood hemoglobin levels. Bevacizumab was given every 3 wk, indicated by asterisks. B. The extent of lymphangiomatosis in the left lung as visualized on chest CT 1 day before (left) and 10 weeks after (right) initiation of bevacizumab treatment. C. Immunohistochemical staining of VEGF-A in proliferative lymphatic vessels (top) vs. unaffected lymphatic vessels from the same area (bottom) (original magnification, ×5). The brown VEGF-A staining is evident in lymphendothelial cells of proliferative lymphangioma vessels (top, inset) (original magnification, ×40) but almost absent in lymphendothelial cells of the vas afferens in a lymph node (bottom, inset) (original magnification, ×40). In addition, the density of lymphendothelial cells is higher in lymphangioma vessels than in the vas afferens, suggesting proliferation of lymphendothelial cells. The lymphatic character of the proliferative vessels was confirmed by staining for VEGFR-3 (data not shown). CT = computed tomography; VEGF = vascular endothelial growth factor.

Grahic Jump Location




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).


Submit a Comment/Letter
Submit a Comment/Letter

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.


Buy Now for $32.00

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.